Allelic Diversity in Human Developmental Neurogenetics: Insights into Biology and Disease  by Walsh, Christopher A. & Engle, Elizabeth C.
Neuron
ReviewAllelic Diversity in Human Developmental
Neurogenetics: Insights into Biology and DiseaseChristopher A. Walsh1,* and Elizabeth C. Engle1,*
1Division of Genetics, Department of Neurology, Manton Center for Orphan Disease Research, and Howard Hughes Medical Institute,
Children’s Hospital, Boston, MA 02115, USA
*Correspondence: christopher.walsh@childrens.harvard.edu (C.A.W.), elizabeth.engle@childrens.harvard.edu (E.C.E.)
DOI 10.1016/j.neuron.2010.09.042
One of the biggest challenges in neuroscience is illuminating the architecture of developmental brain disor-
ders, which include structural malformations of the brain and nerves, intellectual disability, epilepsy, and
some psychiatric conditions like autism and potentially schizophrenia. Ongoing gene identification reveals
a great diversity of genetic causes underlying abnormal brain development, illuminating new biochemical
pathways often not suspected based on genetic studies in other organisms. Our greater understanding of
genetic disease also shows the complexity of allelic diversity, in which distinct mutations in a given gene
can cause awide range of distinct diseases or other phenotypes. These diverse alleles not only provide a plat-
form for discovery of critical protein-protein interactions in a genetic fashion, but also illuminate the likely
genetic architecture of as yet poorly characterized neurological disorders.Human Genetic Diseases Represent Saturation
Mutagenesis
The accelerating pace of human disease gene identification
continues to amaze and impress. The notion that the six to seven
billion humans on our planet can be conceptualized as a satura-
tion mutagenesis experiment of nature, in which every gene in
the genome has been mutated at least once and can potentially
be scored for phenotypes, is not new (Brenner, 2003; Walsh,
1999). However, it has been brought into clearer focus by the
accelerating pace of disease gene identification. In an experi-
mental situation in which mutations are deliberately created in
animal models (e.g, worms, flies, or zebrafish), a conventional
Poisson statistic provides a rough guide: when three indepen-
dent alleles of an average-size gene have been observed, 95%
of other genes in the genome have been mutated; and when
five independent mutant alleles are observed, 99% of other
genes have been mutated. Extrapolating these animal model
experiments to humans, where there are many well-character-
ized diseases with dozens or hundreds of independent alleles
identifiable as causing a similar disease phenotype (Figure 1
and Table 1), instructs us that humans far exceed the criteria
needed to be certain that all genes in the genome have been
mutated repeatedly.
Many diseases represent special mutations that do not merely
compromise function, but might also create a new, abnormal
biochemical function or constitutively activate the protein or
might create a dominant-negative allele. As we will review, these
unusual mutations are often recurrent, meaning that the identical
mutation has occurred multiple times in different unrelated
patients around the world. Since the probability of mutation at
one codon is similar to the probability of mutation at another
codon (save for the greater tendency for the sequence ‘‘CG’’
to bemutated than other dinucleotide combinations), this implies
that the other codons in the gene are mutated in different
patients somewhere in the world, although potentially resulting
in a different special mutation and a different phenotype. More-over, for the most densely studied genes, such as globin genes,
it appears that virtually every codon in the gene has had a corre-
sponding disease-causing mutation observed, suggesting that
almost every codon in the genome is present in a mutated
form in someone, somewhere. Therefore, humans represent
the richest sort of saturation mutagenesis experiment, one that
we are unlikely to observe in any animal model anytime soon.
Here we will review, using examples from human develop-
mental brain diseases, how the density and diversity of muta-
tion—which we are only beginning to decode—can eventually
be harnessed to go beyond merely associating a gene with
a disease. The unusual mutations create linkages from protein
to protein, by identifying special protein interaction interfaces,
or can represent something like conditional mutations of mice,
in which the expression of a gene may be removed only from
a particular place or domain. This range of mutation, a delicious
biological tool for dissecting mechanisms for the neuroscientist,
is also an uncomfortable fact of life for the human geneticist: this
mutational diversity, or heterogeneity, helps explain the as yet
unexplored allelic diversity of human neurological disorders
and the inherent difficulty in identifying underlying causes of
many neurogenetic diseases.
Loss of Function Mutations Implicate Essential Gene
Functions
DCX illustrates perhaps a typical mutational spectrum for a gene
that basically causes one disease, albeit one with milder and
more severe forms. Null mutations in DCX cause a profound
defect in neuronal migration in males, called lissencephaly, in
which the brain is smooth rather than folded, reflecting severely
abnormal neuronal organization because of defects in migration
of essentially all cortical neurons (des Portes et al., 1998; Glee-
son et al., 1998). Since DCX is an X-linked gene, females show
a milder condition in the heterozygous state; they have a rela-
tively normal appearing cortex, with a second, double cortex in
the subcortical white matter. Neurons appear to migrate eitherNeuron 68, October 21, 2010 ª2010 Elsevier Inc. 245
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Figure 1. Comparison of Mutational Patterns, and Primary Amino Acid Conservation, for Several Genes with Important Neurodevelopmental
Functions
Schematics of each protein are illustrated with the name of the protein and its abbreviation to the upper left followed by mode of inheritance of disease (XL =
X-linked, AD = autosomal dominant, AR = autosomal recessive). Proteins are ordered according to length, with the shortest on the top and the longest on the
bottom, and are presented in three differently scaled groups, each based on the amino acid scale bar found to the upper right of the group. ‘‘Stop’’ mutations
(including nonsense, frameshift, intragenic deletions, or splicing alleles that cause frameshifts) are represented by red dots positioned below the protein corre-
sponding to the location of the mutation. Missense mutations are represented by arrowheads positioned above the protein corresponding to the location of the
mutation. Each dot and arrowhead represents a unique mutation. Additional arrowheads aligned directly above (or red dots aligned directly below) one another
indicate distinct mutations that have been reported at the same amino acid residue (e.g., in KIF21A, the mutation altering an amino acid residue in the distal motor
domain has been identified in three unrelated patients). Some arrowheads or red dots are unevenly stacked; they represent unique mutations that, for reasons of
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Reviewnormally or abnormally depending upon which X chromosome is
active. Cells that transcriptionally inactivate the X chromosome
carrying the X-linked mutation seem to have normal migration
because they have normal levels of DCX activity, although
normal cells can occasionally be obstructed by Dcx-deficient,
arrested neurons (Bai et al., 2003). Cells that inactivate the
normal DCX gene arrest in the subcortical white matter because
they lack DCX activity. Most patients show the full-blown brain
malformation, although mild alleles that only partially impair
DCX function can cause seizures with a normal-looking brain,
or even cause isolated mental retardation with a normal-looking
brain (Guerrini and Marini, 2006; Guerrini et al., 2003).
Mutations in DCX that block the formation of a full-length
protein include nonsense alleles, frameshift alleles, intragenic
deletions, and splicing alterations that result in frameshift alleles.
Wewill refer to these protein-truncatingmutations collectively as
‘‘Stop’’ mutations. Alternatively, missense mutations that alter
individual amino acids might preserve a full-length protein but
render it dysfunctional. Of the more than 60 known mutations
of DCX (many of which are summarized schematically in Fig-
ure 1), the missense alleles slightly predominate over the Stop
alleles. Stop alleles are distributed quite evenly over the length
of the protein, in no obvious pattern, and wherever the protein
is truncated, the result is an equally severe phenotype. This
suggests that full-length DCX is required for normal function
and that anymutation that truncates the protein blocks its normal
function.
In contrast to the even distribution of Stop mutations in DCX,
missense mutations are notably clustered in two repeated
domains, called ‘‘doublecortin’’ domains (N-DC and C-DC in
Figure 1). There are a few missense mutations that affect the N
terminus of the protein or the short linker separating the double-
cortin domains, but strikingly there are no missense mutations
over the C-terminal 100 amino acids of the protein. The impor-
tance of the doublecortin domains for binding of DCX protein
to microtubules was shown on the basis that these missense
mutations block the ability of DCX to bindmicrotubules or tubulin
(Gleeson et al., 1999; Sapir et al., 2000; Taylor et al., 2000). The
clustering of missense mutations in the doublecortin domains
strongly suggests that the three-dimensional structure of these
domains is essential for the normal function of DCX, which is
to bind and organize microtubules in migrating neurons (Kim
et al., 2003; Reiner et al., 2006). On the other hand, the function
of the C terminus is less clear. The Stop mutations suggest that
the C terminus is essential, but the absence of C-terminal
missense mutations suggests that the particular amino acid
sequence of this region may be less important, or perhaps thatscale, were not able to be aligned horizontally along the protein. When multiple un
times that mutation has been independently observed appears above the arrow (o
a distinct disease phenotype, and red arrowheadsmean that the missense mutati
phenotype results frommutations in a given protein, the arrowheads and circles ar
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CHN1 and ROBO3 were predicted with the UCSC genome browser multiple-seq
(uc# noted in Table 1), and the dog sequence for KIF21a was predicted from gemissense mutations in the C terminus might cause a different
disease.
Like many X-linked mutations, autosomal mutations often act
in a recessive fashion, except that for autosomal-recessive
genes both copies of the genemust bemutated in order to cause
disease, with mutation of one allele being asymptomatic and
disease generally caused by an absence of functional protein.
This pattern is nicely illustrated by homozygous or compound
heterozygous mutations in the ROBO3 gene (encoding
the axon guidance receptor ROBO3/Rig-1), which cause the
disorder horizontal gaze palsy with progressive scoliosis
(HGPPS) (Chan et al., 2006; Jen et al., 2004). HGPPS is charac-
terized by absent horizontal gaze from birth (an inability to move
the eyes to the left or right) followed by development of scoliosis,
or curvature of the spine, within the first decade of life. In addi-
tion, axons in the descending corticospinal and ascending
sensory tracts fail to cross the midline in the medulla, and thus
do not decussate to the opposite side as they normally do in
unaffected individuals (Jen et al., 2004). This is similar to the
Robo3/mouse, in which both axons and neurons in the devel-
oping hindbrain and spinal cord fail to decussate across the
midline (Marillat et al., 2004; Sabatier et al., 2004).
Similar to DCX, human mutations in ROBO3 represent
a roughly equal mixture of Stop mutations and missense muta-
tions (Figure 1). The clinical features of patients with missense
mutations cannot be distinguished from those with Stop muta-
tions, suggesting that all mutations eliminate the function of
the ROBO3 protein. Also similar to DCX, the missense changes
predominate at the N terminus of the protein, where they high-
light extracellular domains of this transmembrane receptor that
are essential for protein-protein interactions. Only one mutation,
a Stop, has been identified in the C terminus of ROBO3 (again
implying that the full-length protein is essential for normal func-
tion). Once again, the notable absence of missense mutations
at the C terminus of the protein suggests that the primary amino
acid sequence of the C-terminal intracellular portion may be less
important, or that mutations in this portion of the protein cause
a different disease.
A pattern of mutation distinct from ROBO3 is seen in another
autosomal-recessive disorder of brain development, micro-
cephaly (i.e., a very small brain). The gene most commonly
mutated in human microcephaly is ASPM (abnormal spindle
microcephaly) (Bond et al., 2002, 2003; Nicholas et al., 2009).
ASPM encodes a huge protein with many tandem repeats of
20–24 amino acids that begin with isoleucine-glutamine, hence
named ‘‘IQ’’ repeats. The Aspm protein localizes to the mitotic
spindle and appears essential for normal mitotic spindle functionrelated patients have been reported with the identical mutation, the number of
r below the red dot). Within each protein, each arrowhead color corresponds to
on results in the same phenotype as the Stop mutation(s). When more than one
e color codedwith a corresponding key to the right of the protein. For example,
type have been reported to harbor the identical missense mutation, while two
tation that alters the same amino acid but to a different residue. Conservation
ble for each gene for human, chimpanzee, dog, mouse, chicken, and zebrafish
the sequences used are listed in Table 1. Complete sequence data for FLNA,
NA sequence and orangutan KIF21a and ROBO3 sequences were substituted.
not available and no substitutions for these were made. Several sequences for
uence alignment tool based on the comparative genomics conservation tracts
nome sequence with N-SCAN.
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Table 1. Protein Motifs, Key Abbreviations, and Sequence
Accession Numbers for Conservation Tracts
Conservation
Tract Protein Motifs
Sequence Accession
Numbers
Doublecortin
(DCX)
N-terminal and C-
terminal doublecortin
domains
NP_000546.2,
XP_529107.2,
XP_853182.1,
NP_034155.2,
NP_989666.1
Chimaerin 1
(CHN1)
N-terminal Src homology
2 (SH2), phorbol esters/
diacylglycerol binding
(C1), and Rac GTPase
activating (RacGAP)
domains
uc002uji.1_hg18,
uc002uji.1_panTro2,
uc002uji.1_canFam2,
uc002uji.1_mm9,
NP_001012970.1,
NP_998165.1
Tubulin, beta
3 (TUBB3)
NP_006077.2,
NP_001038974.1,
XP_860049.1,
NP_075768.1,
NP_998655.1,
NP_001026769.1
Roundabout
homolog 3
(ROBO3)
Immunoglobulin-like (Ig),
fibronectin-like (Fn3),
transmembrane, and
conserved cytoplasmic
(CC) domains
ROBO3 NP_071765.2,
uc001qbc.1_ponAbe2,
XP_546425.2,
XP_001476890.1,
NP_571557.1
WD repeat
domain 62
(WDR62)
WD40 (W) domains NP_001077430.1,
XP_512609.2,
XP_853669.1,
XP_896469.1,
XP_699579.2.
Kinesin family
member 21A
(KIF21A)
Motor (M), coiled-coil
(CC), and WD40 (W)
domains
NP_060111.2,
XP_002823145.1, N-
SCAN (chr27.18.003.a),
NP_060111.2,
XP_001920258.1,
XP_415936.2.
FilaminA,
alpha (FLNA)
Calpain-homology (CH)
and immunoglobulin-like
(Ig) domains
NP_001104026.1,
XP_001091073.1,
XP_867483.1,
NP_034357.2,
NP_989905.1,
XP_001922206.1.
Abnormal
spindle
homolog,
microcephaly
associated
(ASPM)
Calpain-homology (CH)
and isoleucine-glutamine
repeat (IQ) domains
NP_060606.3,
NP_001008994.1,
XP_537130.2,
NP_033921.3,
XP_001923712.1,
XP_422197.2.
Key abbreviations for Tubulin, beta 3 (TUBB3): CFEOM, congenital
fibrosis of the extraocular muscles; FW, facial weakness; PN, peripheral
neuropathy; DD, intellectual and social developmental delay; and CJC,
congenital joint contractures.
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Review(Fish et al., 2006; Kouprina et al., 2005). In striking contrast to
ROBO3 and DCX mutations, however, all but one of the more
than 90 knownmutations inASPM associatedwithmicrocephaly
represent Stop mutations of one kind or another (Figure 1) (Bond
et al., 2002; Kousar et al., 2010; Nicholas et al., 2009). Once
again, these Stop mutations occur virtually anywhere along the248 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.coding region of the gene, with no apparent relationship between
the location of the mutation and the severity of the disease. Only
a singlemissensemutation has ever been reported inASPM, and
it alters one of the highly conserved ‘‘Q’’ codons in one of the IQ
repeats (Gul et al., 2006). A similar pattern of mutation is seen in
several other microcephaly genes that comprise other compo-
nents of the mitotic spindle: CDK5RAP2, CENPJ (Bond et al.,
2005), and STIL (Kumar et al., 2009), in which most or all known
mutations are Stop mutations.
A potential explanation for the apparent absence of missense
mutations in ASPM is provided by recent analysis of another
microcephaly gene, WDR62. This gene has been identified as
causative for several distinct but related conditions: Stop muta-
tions cause severe phenotypes, in which severe microcephaly
is associated with abnormal gyral pattern of the brain, clefts in
the brain (schizencephaly), and abnormal neuronal migration,
suggesting markedly abnormal histological organization of the
brain (Bilgu¨var et al., 2010) (Nicholas et al., 2010; Yu et al.,
2010). In contrast, some missense mutations in the same gene
are responsible for a milder form of microcephaly, with less
severe reduction of brain size and less evidence for abnormal
brain histology (Bilgu¨var et al., 2010; Nicholas et al., 2010; Yu
et al., 2010) (Figure 1). Hence, it appears that complete loss of
gene function (due to Stop mutations or occasional missense
changes that severely block protein function) and partial loss of
function lead to different conditions that are not always easily
recognized as allelic. Therefore, one possibility is that missense
mutations in ASPM, STIL, CDK5RAP2, or CENPJ also exist, but
cause a milder disease that has so far not been recognized as
allelic to the more severe syndromes. An alternate explanation
is that perhaps the length of these proteins ismore critical to their
function than is their primary amino acid sequence.
Comparative genomics provides some insight into thepatterns
of disease-causingmutations, since interspecies conservation of
primary amino acid sequence reflects evolutionary selection, i.e.,
the extent to which the exact amino acid sequence is essential to
normal function. Interspecies conservation of amino acid
sequence reflects the fact thatmost changesof conserved amino
acids are deleterious in that they reduce reproductive fitness, re-
flecting a decreased likelihood of their transmission to the next
generation. The most common cause of reduced human fitness
is of course disease, especially when we are talking about the
brain. Aswe recovermore andmore diseasemutations, the theo-
retical concept of negative evolutionary selection, inwhich amino
acid sequence tends to be conserved because alterations cause
reduced fitness, begins to come alive. In the case of DCX, the
relative absence of disease-causing mutations in the C terminus
correlates with a relative lack of amino acid conservation in this
region between species. This contrast suggests that there may
be diseases associated with missense mutations of the C
terminus, but that these diseases have not yet been recovered,
i.e., patients with these other diseases have not yet had their
DCX gene sequenced. Alternatively, many polymorphisms at
the C terminus of DCX may not be deleterious, i.e., don’t cause
any disease. A very similar pattern is seen with ROBO3, where
the lack of missense mutations at the C terminus is matched by
a relatively lower level of amino acid conservation at the C
terminus of the protein.
Neuron
ReviewInterspecies comparisons of the ASPM microcephaly gene
have generated an entire field unto itself, with evidence from
multiple labs suggesting that the overall amino acid sequence
is under less strong negative selection than most human
proteins. In fact, ASPMmay have been a target of positive evolu-
tionary selection, with greater changes in amino acid sequence
between humans and nonhuman primates than most genes,
suggesting a potential role of ASPM in the evolution of the larger
brains that characterize humans (Evans et al., 2004; Kouprina
et al., 2004; Mekel-Bobrov et al., 2005; Yu et al., 2007, 2009;
Zhang, 2003). Analysis of amino acid conservation of ASPM
among vertebrates shows remarkably low conservation
compared to other neurological disease genes (Figure 1). Large
chunks of the protein near the N terminus, and within the IQ
repeats, show extremely low conservation because these
segments of the protein are lacking in rodents and nonmammals
altogether. On the other hand, the region surrounding the calpo-
nin homology (CH) domains is extremely highly conserved, yet
still no missense mutations have been seen here yet. Thus, the
degree of amino acid differences between species does not
suffice to explain the scarcity of missense mutations identified
in all of these genes in patients with known phenotypes, suggest-
ing that some missense changes may have other phenotypic
consequences.
Dominant mMutations Can Implicate Specific
Protein-Protein Interactions
While some dominant mutations function through reduced gene
dosage, many are missense mutations that cause disease by
creating new or aberrant functions in a protein. Thus, the
patterns of dominant mutations are often very different from
those of autosomal or X-linked recessive mutations. This is illus-
trated nicely by the special mutations identified in CHN1,
KIF21A, and TUBB3, each of which alters rather than eliminates
the function of the encoded protein, causes aberrant axon
growth and guidance, and results in an autosomal-dominant
complex eye movement disorder.
Heterozygous mutations in CHN1 cause stalling of axons of
the abducens nerve, one of the three cranial nerves that control
eye movement, and result in a stereotypical pattern of abnormal
horizontal gaze referred to as Duane retraction syndrome (Chan
et al., 2010; Miyake et al., 2008). CHN1 encodes a2-chimaerin,
a RacGAP signaling molecule that turns active GTP-bound Rac
off by enhancing the conversion of GTP-bound Rac to inactive
GDP-bound Rac and has been shown to serve as an effector
for axon guidance (Brown et al., 2004; Iwasato et al., 2007).
CHN1mutations are all missense, the opposite of ASPM. At first
glance, the mutations appear to be somewhat randomly scat-
tered onto the 2D structure of the protein, residing both within
and between its known functional domains (Figure 1). These
are, however, special mutations as each has been shown to hy-
peractivate a2-chimaerin’s normal function and to pathologically
lower RacGTP levels in the cell (Miyake et al., 2008). Most muta-
tions appear to do this by altering amino acid residues involved in
intramolecular interactions that normally stabilize the closed,
inactive conformation of the molecule. By substituting a different
amino acid, the inactive conformation is destabilized and the
activity of the signaling molecule is pathologically enhanced.Heterozygous mutations in KIF21A result in a different auto-
somal-dominant stereotypical congenital eye movement
disorder, congenital fibrosis of the extraocular muscles (CFEOM)
type 1, which probably results from the stalling ormisguidance of
axons in another ocular cranial nerve (the oculomotor nerve) that
normally innervates several extraocular muscles important for
horizontal and vertical gaze (Yamada et al., 2003). KIF21A
encodes a kinesin motor protein that transports cargo from the
neuronal cell body to the developing axon’s growth cone by
‘‘walking’’ along microtubules (Marszalek et al., 1999). KIF21A
mutations are all missense, are typically recurrent, and often
arise as de novo mutations in children of unaffected parents
around theworld. As highlighted in Figure 1, these raremutations
repeatedly alter specific highly conserved amino acid residues
located within two regions of this very large protein, the third
coiled-coil domain of the stalk region and the distal motor
domain. Remarkably, the most common missense mutation,
2860C > T (R954W), is present in 61 of the 84 patients reported
to date, and 72 of the 84 have mutations altering the KIF21A
R954 residue. This specificity leads to the prediction that the
mutations disrupt specific protein-protein interactions, and
thus that they provide a biological tool for dissecting both
disease mechanism and the subfunctions of the altered kinesin
domains. Notably, unaffected control individuals have been
found to harbor missense polymorphisms that map to the distal
stalk of KIF21A. Unlike the disease mutations, these nonpatho-
genic changes alter amino acids that are poorly conserved in
other species and thus are not under negative evolutionary
selection and are not critical to KIF21A function (Yamada et al.,
2003). In contrast, no KIF21A Stop mutations have been
reported in CFEOM1 patients or controls, suggesting that
heterozygous Stop mutations may be embryonic lethal or result
in a different, unrecognized human disorder.
Finally, heterozygous missense mutations in TUBB3 cause
a third congenital eye movement disorder, CFEOM type 3,
that, in some patients, is indistinguishable from the KIF21A
phenotype and also results from aberrant guidance of oculo-
motor cranial nerve axons (Tischfield et al., 2010). TUBB3
encodes the neuronal-specific b-tubulin isotype III, a component
of the microtubule cytoskeleton on which kinesins walk. Similar
to KIF21A disease mutations, TUBB3mutations are also special:
they are missense and often arise de novo, and the same muta-
tion is found among multiple unrelated patients (Figure 1). Unlike
mutations in CHN1 and in KIF21A that result in isolated and
stereotypical ocular phenotypes, these TUBB3 mutations
demonstrate allelic diversity, with specific missense mutations
causing additional phenotypes, including facial weakness,
progressive peripheral neuropathy, congenital joint contrac-
tures, and/or developmental disabilities (Figure 1) (Tischfield
et al., 2010). Studies of both humans and a mouse model reveal
aberrant axon growth and guidance without evidence of errors in
cortical neuronal migration. All mutations increase microtubule
stability, while a subset appears to alter microtubule-kinesin
interactions. Thus, these repetitive human mutations highlight
and hence identify interfaces on TUBB3 that are essential to
specific subfunctions of this tubulin isoform that are critical to
the development and maintenance of axons in both the central
and the peripheral nervous system.Neuron 68, October 21, 2010 ª2010 Elsevier Inc. 249
Neuron
ReviewSome Genes Are Subject to Multiple Types of Mutations
Associated with Different Diseases
If specific dominant heterozygous mutations in CHN1, KIF21A,
or TUBB3, all three of which encode proteins expressed in
neurons throughout the developing and mature nervous system,
lead to new enhanced or aberrant protein function that cause
specific eye movement defects, what would we expect to be
the effects of different mutations altering other conserved resi-
dues in these same genes? For TUBB3, this question was
answered, in part, by the recent report of a second set of domi-
nant missense human mutations that result in less stable, rather
than more stable, microtubules and cause malformations of
cortical development secondary to neuronal migration defects,
in the absence of CFEOM type 3 (Figure 1) (Poirier et al., 2010).
Thus, this new set of missensemutations probably alter residues
essential to different subfunctions of the TUBB3 protein.
Although human loss-of-function mutations have not been
identified for CHN1, KIF21A, or TUBB3, we might get insights
of what to expect from engineered mouse models. Indeed,
Chn1/mice survive and have a completely different phenotype
from the phenotype found to result from missense mutations in
humans (Miyake et al., 2008); the mice have misguidance not
of cranial but of corticospinal axons, resulting in an abnormal
hopping gait (Iwasato et al., 2007). This suggests that human
CHN1 Stop mutations might underlie a yet-to-be-identified neu-
romotor disorder.
There are other developmental examples where different sorts
of mutations in the same gene can cause two or more different
diseases, often with almost no overlap, as a result of differing
biochemical mechanisms. Mutations in FLNA are one nice
example: FLNA mutations include loss of function, gain of func-
tion, and partial loss of function, and each mutation type results
in a distinct phenotype (Feng andWalsh, 2004b) (Figure 1). FLNA
encodes FilaminA, and the first known disease associated with
loss of FLNA function was periventricular heterotopia, a neuronal
migration disorder in which neurons fail to migrate out of the
ventricular zone during prenatal development (Fox et al., 1998).
The disorder is X linked, typically prenatally lethal in males, and
is associated with many Stop mutations that block normal
protein translation from that locus (as opposed to making a trun-
cated protein) (Sheen et al., 2001). FLNA is essential for normal
heart and vascular development as well, explaining the prenatal
lethality of the condition (Feng et al., 2006; Hart et al., 2006).
Several FLNA missense mutations cause an indistinguishable
phenotype, presumably by also acting as heterozygous null
mutations (Sheen et al., 2001; Sole´ et al., 2009), and these
tend to cluster in the exons encoding the first calpain-homology
(CH) domain, required for actin binding (Parrini et al., 2006).
Occasionally male patients who harbor FLNA mutations survive
and have periventicular heterotopia; these mutations are often
missense changes, or alleles that only truncate the extreme C
terminus, suggesting that theymay create hypomorphic proteins
that retain some residual function (Parrini et al., 2006; Sheen
et al., 2001; Sole´ et al., 2009).
After the initial discovery of null mutations associated with
periventricular heterotopia, an amazing array of skeletal dyspla-
sias have been described in association with FLNA mutations,
including many with unusual or recurrent missense mutations;250 Neuron 68, October 21, 2010 ª2010 Elsevier Inc.these include otopalataldigital (OPD) syndrome I and II, fronto-
metaphyseal dysplasia, and Melnick-Needles syndrome
(Robertson, 2005; Robertson et al., 2003). Even more recently,
additional specific mutant alleles of this same gene have been
associated with inherited X-linked myxomatous valvular
dystrophy (XMVD) affecting primarily the heart (Kyndt et al.,
2007) and with terminal osseous dysplasia (TOD), which has so
far been seen with a single mutant allele that has recurred in
separate families at least six times (Sun et al., 2010). Many of
these disorders do not show periventricular heterotopia, sug-
gesting that the mutations do not remove FilaminA function but
may alter it. Only one reported allele causes both OPD and peri-
venticular heterotopia (Zenker et al., 2004). Many OPDmutations
cluster in the second CH domain, which also regulates actin
binding. Recent work suggests that at least some of the OPD
missense mutations actually enhance the binding of FilaminA
to F-actin in vitro, resulting in a gain-of-function mechanism
(Clark et al., 2009), whereas the periventricular heterotopia
missense mutations presumably disrupt actin binding.
The large number of disease-associated alleles found in FLNA
might be predicted by the very high conservation of its amino
acid sequence between species. Moreover, the seven or more
distinct genetic disorders resulting from different mutations in
the same gene suggest that FilaminA has diverse interaction
with many different other protein networks in distinct develop-
mental contexts, and the long list of filamin-interacting proteins
further supports this hypothesis (Feng andWalsh, 2004a). These
allelic disorders provide direct pointers into distinct signaling
pathways. They also prompt the question of the hidden allelic
diversity of other genes, in which a single gene can be affected
in many ways to cause widely divergent phenotypes.
How Do the Missing Mutant Alleles Map onto
Uncharacterized Diseases?
Comparisons of the sorts of mutations that cause developmental
phenotypes reveal remarkable differences from gene to gene,
given that the pattern of disease-associated mutation reflects
not only patterns of DNA mutation, but also structures and func-
tions of proteins, and the extent to which amino acid sequence is
conserved. Some genes (ROBO3, DCX, FLNA) cause develop-
mental disorders as a result of apparently simple loss-of-func-
tion mechanisms, either by Stop mutations or by missense
changes that are presumably also disabling. FLNA shows one
phenotype due to loss of function, but other phenotypes due
to gain or alteration of function, while TUBB3 shows distinct
phenotypes due to different gain or alteration in function, with
specific missense mutations targeting specific protein-protein
interactions. Dominant mutations in KIF21A and CHN1 appar-
ently also act by disrupting normal protein-protein interactions.
Notably, simple loss-of-function mutations in TUBB3, KIF21A,
and CHN1 have not yet been observed and might have
completely different phenotypes. Thus, if we assume that hu-
mans are saturated for mutations at most codons (as well as
presumably some, but certainly not all, noncoding segments),
the depth of mutational analysis in humans allows one to begin
to ask questions about what alleles we are missing. For diseases
that are familiar as dominant, gain-of-function conditions,
are there additional unrecognized phenotypes resulting from
Neuron
Reviewgain-of-function mutations altering a different set of conserved
amino acids? What is the loss-of-function phenotype in that
same gene, and does it look at all like the dominant disease?
In some cases it might, yet in others it could be embryonically
lethal or have a totally different phenotype. Or, if we have
observed the null phenotype for a gene, then what are that
gene’s hypomorphic phenotypes, since our previous analysis
suggests that hypomorphic mutations frequently exist? For
many genes with essential roles in brain development, it is likely
that the possible range of alleles has not yet been identified, and
presumably many of these other types of alleles disrupt brain
function but remain so far unrecognized.
So then we might ask, what diseases, or other phenotypes,
do these missing alleles cause? Where does the burden of
unexplained neurogenetic disease lie? In the case of severe
developmental disorders of the brain, associated with neonatal
presentations with epilepsy, brain malformations, or mental
retardation, these disorders are remarkably well characterized,
with clinicians having a greater than 60% chance of identifying
a specific causative condition or responsible gene (Rimoin and
Emery, 2007). For milder forms of intellectual disability, the yield
of genetic investigation is lower, approximately 50% (Rimoin and
Emery, 2007). For autism, which is a milder and more heteroge-
neous condition, intensive genetic investigation typically reveals
a specific (genetic) cause (or a specific, complex interaction of
rare and/or common alleles) in 15%–20% of cases (Pinto et al.,
2010; Shen et al., 2010), leaving the great majority as yet unex-
plained. And finally, for the mildest learning disorders and
psychiatric conditions, it is safe to say that a specific genetic
contribution of less than 5% can presently be explained, leaving
these disorders almost completely uncharacterized genetically
(Faraone and Mick, 2010; Owen et al., 2010).
Recent studies of the genetics of autism spectrum disorders
(ASDs), described in greater detail in another review in this issue
of Neuron (State, 2010), show how heterogeneous the milder
developmental disorders might be. Perhaps 5% of children
with ASD have mutations in Mendelian autism genes that typi-
cally cause ASD in some children and intellectual disability in
other children; these genes include FMR1, MECP2, NLGN2,
NLGN3, ARX, SHANK3, TSC1, TSC2, and others (Walsh et al.,
2008). Heterozygous copy-number variants (CNVs) appear to
be collectively the most common cause of ASD, though esti-
mates of the proportion of the disorder that they are responsible
for range widely frommore than 20% in early studies to closer to
5% in more recent and systematic studies (Sebat et al., 2007;
Shen et al., 2010; Weiss et al., 2009). About a half dozen of these
rare CNVs are recurrent, meaning that deletions or duplications
of the same regions occur in more than one family (16p11.2,
15q, 22q11, 15q13, NRXN1, MECP2), and so are recognizable
as causative when observed in isolation; others appear to be
unique in each family. Common alleles have been described
that might affect predisposition to ASD, but to date they would
account for even less of the known genetic risk (Anney et al.,
2010; Arking et al., 2008; Glessner et al., 2009). These sorts of
heterogeneous disorders might be where we find many of the
miscellaneous missing mutations, and the specific mutations
involved could be individually rare, present in just one or small
numbers of families, and very diverse in their action.An interesting sort of mutation, found in a few ASD patients
whose parents share common ancestry (and who hence share
more than the usual proportion of their rare genetic mutations),
has recently been described andmay point to a whole new cate-
gory of alleles. These mutations are homozygous deletions,
removing both copies of a stretch of DNA. Homozygous
deletions can remove genes, making them conventional Stop
mutations, but in some patients appear to delete noncoding
DNA containing conserved predicted promoter-enhancer
elements near genes with prominent brain expression (Morrow
et al., 2008). These homozygous noncoding mutations show an
appealing resemblance to conditional mutant alleles in mice,
where the function of a gene might not be compromised in all
places and times, but only where that gene’s expression would
have been controlled by deleted promoter elements. Thus, the
possible mutations that appear to cause ASD are diverse and
heterogeneous not only in the genes involved, but also in the
mechanisms involved (deletion, duplication, conventional point
mutation) and mode of inheritance or absence of inheritance.
With the advent of high-throughput sequencing of the entire
exome, or genome, one of the biggest challenges will be inter-
preting which rare polymorphisms in a person’s DNA are likely
to be causative of disease. There is little doubt that one of the
biggest immediate impacts of high-throughput sequencing in
the clinical setting will be in expanding the range of mutation of
known genes, in addition to new gene identification. Finding
new alleles of known genes is simpler, since we already have
some knowledge of overall gene function, but will provide a rapid
bounty of biological information about interactions and path-
ways as well as causes of disease.
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